Researchers at the Arc Institute developed programmable bridge recombinases, RNA-guided enzymes capable of executing large-scale genomic rearrangements in human cells. This technology enables precise insertion, deletion, and inversion of DNA segments up to a million base pairs, advancing capabilities beyond conventional gene editing methods that focus on single base changes. The system is poised to revolutionize gene therapy by enabling treatments acting on entire genomic regions, greatly expanding the scope of addressable genetic diseases. Published work demonstrates up to 20% insertion efficiency with megabase-scale genomic manipulation.